Health and Healthcare
Another Stent Failure For Boston Scientific (BSX)
Published:
Last Updated:
Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical research community for over a year fighting the perception that its drug-coated stents may be unsafe.
Comments about the potential danger of stents has sharply cut their use for treatment of cardiovascular disease.
The latest research on stent use compared to open heart surgery indicates that stents are relatively less effective. According to Reuters, "Despite the advent of drug-eluting stents, surgery comes out a winner," Douglas Weaver, president of the American College of Cardiology.
If the study results had fallen the other way, BSX might have hoped for a pick-up in sales of one of its most important products.
No such luck. Shares in Boston Scientific trade at $13, down from $44 a little over four years ago.
Douglas A. McIntyre
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.